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Dr Matthew Edwards (Winston-Salem, NC). Good morn-
ing. I would like to thank the Society and the program committee
for the opportunity to discuss this presentation on the topic of
predicting long-term blood pressure responses following renal
artery stenting. I would also like to congratulate Dr Beck on his
presentation.
Treatment of renovascular disease is a highly controversial
topic in 2009. Eighteen months ago, Drs Richard Cambria, Rob-
ert Zwolak, and I performed variable roles at a meeting of the CMS
[Centers for Medicare and Medicaid Services] Medical Evidence
Development and Coverage Advisory Committee regarding reno-
vascular disease treatment. At that meeting it was very clear that
renal artery stenting has come under the microscope of scrutiny by
the nation’s largest third payor. The principle topic of discussion
was the lack of any meaningful controlled data demonstrating
efficacy of stenting in improving outcomes and, more specifically,
outcomes of reducing subsequent cardiovascular disease events,
preventing dialysis dependence, and improving survival free of
these problems. A prolonged discussion of the most appropriate
means of procuring such data was discussed, and several proposals
of limiting reimbursement for stenting, similar to those currently
employed for carotid artery stenting, were voted upon. Ultimately,
the decision was made by the group to recommend continued
funding of renal stenting until data from currently enrolling trials
such as CORAL [Cardiovascular Outcomes in Renal Atheroscle-
rotic Lesions] were completed. Given the heightened scrutiny,
reimbursement policies will almost certainly be revisited at that
time.
Two of the issues prompting that meeting were (1) known
variability of early results following renal artery stenting and (2) the
lack of durability of those results. In this presentation Dr Beck
describes 129 patients treated, with only 16% experiencing im-
proved renal function, 24% having worsened renal function, and
45% to 55% having improved hypertension, with 40% of these
having subsequent deterioration of their hypertension response.
Moderate to severe chronic kidney disease in female gender were
identified as significant and independent predictors of deteriorat-
ing response. I have several questions for Dr Beck.
First, I would like some clarification on the issue of restenosis.
Your group reports a very high rate of restenosis approximating
50% at 18 months. Only 27% of these patients received repeat
intervention. What clinical manifestations did you observe in these
patients and how did you approach their treatment? While I
understand that you are looking for identifiable preoperative risk
factors for poor hypertension response to guide future patient
selection, I think that you must consider or adjust for this known,
time-dependent cause of recurrent hypertension in your analyses
or risk type I error by not considering its potential confounding
effects.
Second, and more importantly, with only 30% to 40% of
patients achieving durable hypertension response, 24% experienc-
ing short-term renal function deterioration, and a 50% rate of
stenosis at 18 months, do you think you are helping or hurting the
majority of patients treated? Also, how will these data impact yourFinally, in your analyses you report that blood pressure re-
sponses did not impact survival, but renal function responses did
impact survival. Don’t you think that looking at predictors of renal
function response might be more important than looking at pre-
dictors of blood pressure response? Again I ask the question, does
this affect your selection criteria for stenting going forward?
I look forward to your answers and thank you again for the
privilege of the floor.
Dr AdamW. Beck. Regarding the restenosis data, I am sorry
I wasn’t here for the presentation, but I saw the abstract that Dr
Corriere presented yesterday, and regarding restenosis there, I
think that yourmedian follow-up was about 5½months, and if you
look at our restenosis rate on a Kaplan-Meier curve, our restenosis
is 50% at 18months, which obviously is a significantly high number
of those patients, and that is based on duplex criteria alone and so
we have selectively reintervene on those patients if they have a
progressive stenosis on duplex, they may get intervention. Obvi-
ously, whether they have had a response to the therapy in the first
place, it is going to impact whether we reintervene or not.
If they have clinical manifestations of their progressive stenosis
or any stenosis on duplex, then we would intervene. So if they
come in with what appears to be renovascular hypertension or
recurrent hypertension, we would then intervene. If they have a
60% restenosis and they are clinically doing well, their hypertension
is controlled, there is not evidence of renal dysfunction, then we
would not reintervene unless they had, again, progressive stenosis
on ultrasound. So those patients, the 27% that are reported in the
paper and not in this presentation, underwent reintervention for
recurrent clinical evidence of stenosis.
Regarding whether we are helping or hurting the patients, I
think that is an excellent question and I think that is the ultimate
question of renal stenting. In terms of the deterioration of renal
function that I presented, all of these patients underwent interven-
tion for renovascular hypertension, not for renal insufficiency, so
the primary goal of their therapy was to treat the renovascular
hypertension, and so whether the renal function improved or not
was not a primary outcome measure, and I think that is probably
more of an indication of the progression of their disease and it may
just be the natural history of their disease, we just don’t know.
I think that the data out there for treating patients for renal
insufficiency with renal stents are definitely very soft, even more
soft than renovascular hypertension, so at this time, we generally
just treat for renovascular hypertension if they happen to have renal
insufficiency, then that is just part of it. Whether I think we may be
hurting some patients, and I think some of the work that you are
doing with embolic protection devices is probably going to end up
being very important, especially in patients that have chronic renal
insufficiency along with renovascular hypertension.
The third question that you are asking about looking at
predictors for renal function response, I think that is a very good
question, and again, our secondary goal of the renal stenting was to
treat the renal insufficiency and so we primarily wanted to look at
predictors of outcome for our primary treatment goal.
